Altimmune to Present at Upcoming Conferences
Details on the H.C. Wainwright fireside chat presentation are as follows:
Title: | |
Presenters: | |
Date/Time: |
A webcast link to the H.C. Wainwright fireside chat presentation will be accessible on the Events section of the Altimmune website.
Details on the NASH-TAG 2021 presentation by Dr.
Title: | Dual GLP-1 Agonists in the Treatment of Metabolic & Liver Dysfunction in NASH |
Presenter: | |
Date/Time: |
A copy of the presentation materials will be accessible on the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
Investor & Media Contacts:
Will Brown | |
Chief Financial Officer | Sr. Dir, Investor Relations |
Phone: 240-654-1450 | Phone : 410-474-8200 |
wbrown@altimmune.com | sjurchison@altimmune.com |
Source: Altimmune, Inc.